CatalystFDA/Bio

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria

Statistically significant OS benefit versus durvalumab in first-line biliary tract cancer.

What changed

Statistically significant OS benefit versus durvalumab in first-line biliary tract cancer.

Why it matters

Statistically significant OS benefit versus durvalumab in first-line biliary tract cancer. — impact context not separately stored; see What changed.

Sources